Furthermore, the modification of the tumor microenvironment through the use of inhibitors targeting cytokine signalling pathways, such as TGF-β and antiangiogenesis inhibitors, such as bevacizumab, can render it more susceptible to the action of the immune system [15,16]. This evidence concerns the gene TGFB1 and neoplasm.